{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:39:11Z","timestamp":1794620351251,"version":"4.9.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jaad.2025.12.088","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:48:10Z","timestamp":1767109690000},"page":"1454-1460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term dupilumab efficacy and safety in moderate-to-severe atopic dermatitis: A real-world single-center retrospective study"],"prefix":"10.1016","volume":"94","author":[{"given":"Yun","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixian","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jaad.2025.12.088_bib1","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.jaad.2025.12.088_bib2","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3510","article-title":"Prevalence and incidence of atopic dermatitis: a systematic review","volume":"100","author":"Bylund","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"10.1016\/j.jaad.2025.12.088_bib3","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamadermatol.2022.3014","article-title":"Dupilumab drug survival and associated predictors in patients with moderate to severe atopic dermatitis: long-term results from the daily practice BioDay registry","volume":"158","author":"Spekhorst","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.12.088_bib4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jaad.2025.12.088_bib5","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/1346-8138.16764","article-title":"Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study","volume":"50","author":"Napolitano","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2025.12.088_bib6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-term efcacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE)","volume":"23","author":"Andrew","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.12.088_bib7","article-title":"Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies","volume":"101","author":"De Bruin-Weller","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2025.12.088_bib8","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3390\/jcm14062077","article-title":"Effectiveness of tralokinumab across atopic dermatitis phenotypes","volume":"14","author":"Barei","year":"2025","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.jaad.2025.12.088_bib9","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1080\/03007995.2021.1933929","article-title":"Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review","volume":"37","author":"Iannone","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.088_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/bjd\/ljae037","article-title":"Towards a patient-centred definition for atopic dermatitis flare: a qualitative study of adults with atopic dermatitis","volume":"191","author":"Dainty","year":"2024","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.12.088_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jaad.2023.01.053","article-title":"Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspective","volume":"89","author":"Yeung","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.12.088_bib12","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.15609","article-title":"Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre","volume":"33","author":"Olesen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.088_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.12.088_bib14","first-page":"1","article-title":"Safety and effectiveness of dupilumab in the real-world treatment of atopic dermatitis in Japan: 1-year interim analysis from a post-marketing surveillance","volume":"3","author":"Saeki","year":"2023","journal-title":"J Cutan Immunol Allergy"},{"issue":"4","key":"10.1016\/j.jaad.2025.12.088_bib15","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/jcm9041241","article-title":"Dupilumab for the treatment of atopic dermatitis in an Austrian cohort-real-life data shows rosacea-like folliculitis","volume":"9","author":"Quint","year":"2020","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.jaad.2025.12.088_bib16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/14740338.2021.1939673","article-title":"Safety of dupilumab in patients with atopic dermatitis: expert opinion","volume":"20","author":"Francuzik","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.jaad.2025.12.088_bib17","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1097\/DER.0000000000000570","article-title":"Psoriatic plaques after initiation of dupilumab therapy","volume":"31","author":"DeGrazia","year":"2020","journal-title":"Dermatitis"},{"key":"10.1016\/j.jaad.2025.12.088_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/ph17010117","article-title":"Assessment of patient-reported outcomes at 48 months of treatment with dupilumab for severe atopic dermatitis: a single-center real-life experience with 126 patients","volume":"17","author":"Francesca","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jaad.2025.12.088_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15385","article-title":"The efficacy and safety of dupilumab for the treatment of atopic dermatitis among Chinese patients in clinical practice: a single-center retrospective study","volume":"35","author":"Li","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2025.12.088_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111137","article-title":"Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis: a preliminary report","volume":"125","author":"Deng","year":"2023","journal-title":"Int Immunopharmacology"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.088_bib21","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1089\/derm.2024.0160","article-title":"Early dupilumab response predicts Pediatric atopic dermatitis disease relapse","volume":"36","author":"Zhao","year":"2025","journal-title":"Dermatitis"},{"issue":"11","key":"10.1016\/j.jaad.2025.12.088_bib22","article-title":"Real-world experience of 3-year treatment with dupilumab: significant decrease in circulating neutrophils and eosinophils in Japanese patients with atopic dermatitis","volume":"33","author":"Hideyuki","year":"2024","journal-title":"Exp Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225034887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225034887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:06:59Z","timestamp":1776406019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225034887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0190962225034887"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.088","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term dupilumab efficacy and safety in moderate-to-severe atopic dermatitis: A real-world single-center retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}